Leading expert in multiple sclerosis, Dr. Paul Matthews, MD, explains how personalized medicine is advancing treatment. He details the importance of real-world clinical effectiveness research. Dr. Paul Matthews, MD, highlights the UK risk-sharing scheme and the MS base consortium. These initiatives demonstrate the benefits of new multiple sclerosis medications. He also discusses promising progress in treating progressive multiple sclerosis forms. New therapies like Ocrelizumab and remyelination treatments offer hope.
More from Multiple Sclerosis
More from Diagnostic Detectives Network
Personalized Medicine and New Treatment Advances in Multiple Sclerosis
Jump To Section
- Breakthroughs in Personalized Medicine
- Real-World Treatment Effectiveness
- The UK Risk-Sharing Scheme
- Global Data Consortiums
- Progressive MS Therapies
- Future Treatment Directions
- Full Transcript
Breakthroughs in Personalized Medicine
Dr. Paul Matthews, MD, discusses major breakthroughs in personalized medicine for multiple sclerosis. He notes the success of having over 11 different multiple sclerosis medications available. This wide choice allows neurologists and patients to select the most appropriate treatment. The goal is to match the right therapy to the right patient for optimal outcomes.
Dr. Paul Matthews, MD, emphasizes the importance of demonstrating clear patient benefits from these expensive medications. Learning from real-world use helps identify which patients receive the most benefit. This approach is a significant stride forward in clinical effectiveness research for MS.
Real-World Treatment Effectiveness
Dr. Paul Matthews, MD, highlights the critical role of real-world evidence in multiple sclerosis care. Neurologists and patients work together to track disease progression. This collaboration provides invaluable data on how treatments perform outside of controlled clinical trials.
Standardized information collection is key to this process. It allows for a clear understanding of a medication's impact on a patient's daily life. This real-world data is essential for validating the effectiveness of new multiple sclerosis therapies.
The UK Risk-Sharing Scheme
A landmark example of effectiveness research is the UK risk-sharing scheme. Dr. Paul Matthews, MD, explains this initiative. Neurologists across the country prescribed first-line disease-modifying therapies using a standardized approach.
They recorded disease progression data into a central registry. Dr. Jackie Palace and colleagues summarized this data, demonstrating clear benefits for UK patients. This scheme proved that these multiple sclerosis medicines provide significant value in a real-world setting.
Global Data Consortiums
Dr. Paul Matthews, MD, points to the MS base consortium as a new model for data collection. This global effort involves voluntary data aggregation from neurologists worldwide. The consortium has begun publishing research on medication effectiveness.
These studies provide crucial data on the relative effectiveness of different multiple sclerosis drugs. They also help identify potentially optimal treatment sequences for patients. This global collaboration is accelerating progress in personalized MS care.
Progressive MS Therapies
A major shift in focus has occurred towards treating progressive multiple sclerosis. Dr. Paul Matthews, MD, describes this as a critical development. The treatment landscape has moved beyond just managing relapsing-remitting forms.
He highlights promising Phase 2 clinical trial results for remyelination therapy. The first reports on Ocrelizumab (Ocrevus) show effectiveness in progressive MS. Numerous other clinical trials are currently in progress, offering new hope for patients with progressive disease.
Future Treatment Directions
Dr. Paul Matthews, MD, concludes by looking at the future of multiple sclerosis treatment. These ten areas of progress highlight a huge range of developments. New medications are set to significantly improve patient prognoses.
Dr. Anton Titov, MD, agrees with this positive assessment. The advances in MS treatment also provide a valuable direction for treating other neurological diseases. The lessons learned from multiple sclerosis research will have far-reaching implications for medicine.
Full Transcript
Dr. Anton Titov, MD: You published a review of multiple sclerosis advances in diagnosis and treatment. It was printed in the leading journal Nature Reviews Neurology. Your review is titled "Decade in review: multiple sclerosis. New multiple sclerosis medications. Personalized medicine for multiple sclerosis."
What are leading breakthroughs in personalized medicine for multiple sclerosis treatment? We have the great success with 11 or more multiple sclerosis medicines on the market now.
Dr. Paul Matthews, MD: These new multiple sclerosis medications give patients and their doctors a wide choice of treatments. They are all expensive. It is important to demonstrate clearly that these medications are providing benefits to the patients with multiple sclerosis.
Patients are using them in real life. We learn from those treatments. We understand who is receiving the most benefits and who might be receiving less benefits.
Clinical effectiveness research in multiple sclerosis is taking big strides forward. Neurologists and patients are working together.
Two big examples of this were the success of the UK risk-sharing scheme. Neurologists all over the country prescribe the first disease-modifying therapy to multiple sclerosis patients. They do so after taking standardized information and recording the progression of disease back to central registry following this standardized therapy choice.
Dr. Jackie Palace and her colleagues published earlier in the year a useful summary of this data. They demonstrated clearly how in real life, in the United Kingdom, these multiple sclerosis medicines provide benefit to the patients who take them.
In the future, there are new ways of doing data collection through voluntary data aggregation from neurologists all over the world. MS base consortium has demonstrated this new experience.
Experts have begun to publish a range of research articles. They demonstrated both the effectiveness of medicines. They showed an ability to provide data on relative effectiveness of multiple sclerosis medications.
They also showed potentially optimal paths for use of medications.
Finally, patients with the progressive multiple sclerosis must be pleased. We moved over the last decade from a time when treatment for multiple sclerosis was only about relapsing-remitting form of multiple sclerosis. Now the focus is largely on controlling or stopping progression of multiple sclerosis.
The first Phase 2 clinical trial results for remyelination therapy are promising. The first reports of Ocrelizumab have been presented. Ocrelizumab (Ocrevus) is effective in progressive multiple sclerosis.
There are also many other clinical trials in progress for progressive multiple sclerosis. I think these 10 areas of progress in multiple sclerosis treatment really highlight a huge range of developments in multiple sclerosis.
New medications will improve prognosis in patients with multiple sclerosis. They will also give us a direction how we can treat other diseases in the future.
Dr. Anton Titov, MD: They will, indeed. Thank you! This is an excellent review of major advances in multiple sclerosis treatment.